Centre Hospitalier Universitaire Dijon
chu-dijon.frTotal trials
486
Active
93
Phase 3
30
Total enrollment
10,380,573
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 58 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone intravitreal implant | — | — | — | — | — | 1 | |
| Fluocinolone Acetonide Intravitreal Implant | — | — | — | — | — | 1 | |
| Blood samples | — | — | — | 24 | |||
| BIOLOGICAL ASSESSMENT | — | — | — | — | 3 | ||
| Tocilizumab treatment | — | — | — | — | — | 2 | |
| Biological check-up | — | — | — | — | 2 | ||
| prednisone treatment | — | — | — | — | 2 | ||
| FOLFOX | — | — | — | — | — | 2 | |
| Dostarlimab | — | — | — | — | — | 1 | |
| Biological study on circulating tumor DNA | — | — | — | — | — | 1 | |
| OM-89 [Uro-Vaxom® Capsule] | — | — | — | — | — | 1 | |
| OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo] | — | — | — | — | — | 1 | |
| Argipressin | — | — | — | — | — | 1 | |
| Chlorure de sodium | — | — | — | — | — | 1 | |
| Insulin + semaglutide treatment | — | — | — | — | — | 1 | |
| Usual insulin treatment | — | — | — | — | — | 1 | |
| "FOLFIRI" cures | — | — | — | — | — | 1 | |
| Trifluridine cures | — | — | — | — | — | 1 | |
| mFOLFOX6 | — | — | — | — | — | 1 | |
| Injection of methylprednisolone | — | — | — | — | — | 1 | |
| Injection of sodium chloride | — | — | — | — | — | 1 | |
| Acetylsalicylic acid/Aspirin | — | — | — | — | — | 1 | |
| mFOLFORINOX | — | — | — | — | — | 1 | |
| Capecitabine or gemcitabine | — | — | — | — | — | 1 | |
| Vasopressin | — | — | — | — | — | 1 | |
| Norepinephrine | — | — | — | — | — | 1 | |
| Methotrexate treatment | — | — | — | — | — | 1 | |
| FOLFOXIRI Protocol | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Alpelisib | — | — | — | — | — | 1 | |
| treatment "intervention" | — | — | — | — | — | 1 | |
| treatment "standard" | — | — | — | — | — | 1 | |
| modified FOLFORINOX | — | — | — | — | — | 1 | |
| Modified FOLFOX | — | — | — | — | — | 1 | |
| Lithium treatment | — | — | — | — | — | 1 | |
| biological monitoring | — | — | — | — | — | 1 | |
| Blood sampling | — | — | — | — | — | 14 | |
| blood sample | — | — | — | — | 17 | ||
| Blood test | — | — | — | — | — | 3 | |
| Urine sample | — | — | — | — | — | 3 |
18 more active programs hidden
Next readouts
- 2024-02-29
- 2025-12
- 2026-03
- 2026-04
- 2026-05
- 2026-05
- 2026-06
- 2026-12
- 2027-01
- 2027-01
Top conditions
- Stroke9
- Diabetes7
- Type 2 Diabetes7
- Septic Shock6
- Obesity6
- Schizophrenia4
- Colon Cancer4
- Overweight4
Frequently asked questions about Centre Hospitalier Universitaire Dijon
- How many clinical trials does Centre Hospitalier Universitaire Dijon have on ClinicalTrials.gov?
- Centre Hospitalier Universitaire Dijon is listed as the lead sponsor on 486 clinical trials in ClinicalTrials.gov, 93 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Universitaire Dijon's trials are in Phase 3?
- 30 of Centre Hospitalier Universitaire Dijon's trials are in Phase 3, spread across 58 active drug programs.
- What therapeutic areas does Centre Hospitalier Universitaire Dijon focus on?
- Centre Hospitalier Universitaire Dijon's most-studied conditions on ClinicalTrials.gov are Stroke, Diabetes, Type 2 Diabetes, Septic Shock, Obesity.
- When are Centre Hospitalier Universitaire Dijon's next clinical trial readouts?
- Centre Hospitalier Universitaire Dijon has 10 upcoming primary-completion readouts tracked here; the soonest is “Benefit of a Flash Dose of Corticosteroids in Digestive Surgical Oncology: a Randomized, Double Blind, Placebo-controlled Trial”, expected around 2024-02-29.